Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: opalapril who wrote (9690)	4/21/1999 1:58:00 AM
From: aknahow	Respond to of 17367

<Together with the fact that since 1997 the DSMB has not found Neuprex efficacy strong enough to call a halt, even as late as its March 1999 meeting> Opala remember the great post by Robert S which indicated that a DSMB could not recommend going against an FDA mandate. If the FDA really did establish a level of mortality it would seem that the DSMB could not recommend a halt if this level had not been reached. At any rate we will all see what actually happened in a short time.

To: opalapril who wrote (9690)	4/21/1999 6:59:00 AM
From: Robert K.	Read Replies (4) \| Respond to of 17367

I think you all might be better served by reading instead of venting. Read what the doctors and scientists are thinking. Does it mean it will work. >NO. >http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10071352&form=6&db=m&Dopt=b Btw-I read the linked article. It was excellent. Also, is it not curious why xoma has the endotoxin paper but still does not link it to its site. Its a great overview of endotoxin theory. IMO All disclaimers apply. Standard K.